Trump's generic drug tariffs will test his pharma strategy

The potential application of tariffs on generic drugs by the Trump administration represents a significant pivot in pharmaceutical trade policy. This strategy aims to address supply chain vulnerabilities but poses challenges for the cost-sensitive generic drug market. Industry stakeholders are closely monitoring how these measures will impact drug affordability and domestic manufacturing incentives. The outcome of this policy will likely determine the future of generic drug sourcing and competition within the United States.